Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Background Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation
antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; …

Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen
(BCMA) have great potentials in autoimmune diseases and could be novel therapeutics for …

In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …

Simple Summary Approved chimeric antigen receptor (CAR) T cells recognize and bind to
only one tumor target (single-targeted CAR T cells, Si-CART) on cancer cells by the special …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …